A life sciences company founded in California has relocated to Arizona, where it plans to accelerate its advanced topical technologies for skin health and microcirculation.
Arteris Bio has moved into a 1,500-square-foot laboratory and office space in the University of Arizona Tech Park in Tucson. The company is led by founder and CEO Bruce Register, who has more than 30 years of experience in scientific research, global pharmaceutical leadership and entrepreneurial ventures.
Arteris Bio’s relocation to Tucson and UA Tech Park was driven in part by the area’s “exceptional environment” for life sciences companies and capital-efficient path for building and scaling businesses, Register said.
“Its collaborative ecosystem and proximity to academic and clinical expertise make it an ideal setting as we advance our topical technology platform,” Register said. “This is about more than a single product — we are building a platform to unlock entirely new approaches to supporting both localized and potentially systemic physiological function through topical science.”
Arteris Bio is developing Redoxiv, a new topical platform to help keep skin healthy and comfortable. The company combines research and product development in the U.S. with clinical work overseas, allowing it to test and refine its technology efficiently while upholding high scientific and regulatory standards.
Redoxiv features a recently patented formulation incorporating amino acid–based systems, bioactive cofactors, and lipid-compatible delivery components designed to support localized physiological function, oxidative balance, and skin barrier dynamics, according to a company release.
Arteris Bio completed multiple human case studies demonstrating clear proof-of-concept results, which are actively guiding final formulation optimization, Register told the Business Journal.
What’s more, the company is advancing both cosmeceutical and pharmaceutical programs. Pilot clinical studies for its lead cosmeceutical product are planned for the third quarter, with a targeted market launch in late 2026 or early 2027, he added.
After decades spent advancing therapies within both startup environments and Fortune 500 pharmaceutical companies, Register founded Arteris Bio in 2025. As the company expands its presence at UA Tech Park, it’s focused on building infrastructure and partnerships to support continued product development and future market entry.
Arteris Bio is actively engaging with angel investors as key early partners in the company’s growth, playing a foundational role in supporting the next stage of development, Register said.
Register is currently the sole proprietor of Arteris Bio, with support from several remote consultants who visit the company’s site periodically as it establishes its laboratory and operational infrastructure.
The company plans to hire a full-time senior technician focused on formulation development and mass spectrometry, along with one to two interns beginning this summer, Register said.
Arteris Bio’s relocation announcement comes days prior to the kickoff of Arizona Tech Week, which takes place April 6-12. The event is expected draw thousands of attendees, including out-of-state and international startups.
Arizona Tech Week features more than 400 events — including founder meetups, keynote panels, tech demos, open houses, pitch competitions and more, some of
which will be hosted at the University of Arizona in Tucson.
As part of the University of Arizona ecosystem, Tech Parks Arizona operates the UA Tech Park and the UA Tech Park at The Bridges. The parks provide infrastructure, specialized facilities and support to help startups scale.
Arteris Bio relocates to University of Arizona Tech Park – Phoenix Business Journal